secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001213900-25-054371
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics receives Nasdaq bid price deficiency notice; effects 1-for-20 reverse split
--------------------------------------------------------------------------------

- Received Nasdaq notice on June 11, 2025: bid price below $1.00 for 30 consecutive business days (Apr 25–Jun 9).
- Not eligible for standard compliance period due to prior reverse stock splits; plans to request a hearing.
- Effected 1-for-20 reverse stock split on June 13, 2025; closing bid price was $7.31.
- No assurance that bid price will remain above $1.00 or that hearing will grant continued listing.
- Common stock (CERO) and warrants (CEROW) continue trading on Nasdaq pending hearing outcome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025054371/0001213900-25-054371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025054371/ea0245650-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-054371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer